• Male or female patients 2 to 11 years of age.

• Confirmed diagnosis of HAE Type I or II.

• For patients ≥20 kg at screening, patient has had at least 1 documented HAE attack in the last year prior to screening.

• Caregiver, as assessed by the Investigator, must be able to appropriately store and administer IMP and be able to read, understand, and complete the diary.

• Investigator believes that the patient and caregiver are willing and able to adhere to all protocol requirements.

• Parent or Legally Authorized Representative (LAR) provides signed informed consent and patient provides assent (when applicable).